GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Down 61.6% in July

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 16,500 shares, a decrease of 61.6% from the June 30th total of 43,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.8% of the shares of the stock are short sold.

GT Biopharma Trading Up 0.5 %

Shares of GTBP stock traded up $0.01 during trading hours on Thursday, hitting $2.76. 4,869 shares of the company’s stock were exchanged, compared to its average volume of 625,997. The firm has a 50 day moving average of $3.24 and a two-hundred day moving average of $4.13. GT Biopharma has a fifty-two week low of $2.60 and a fifty-two week high of $10.66.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($2.12) EPS for the quarter, beating the consensus estimate of ($2.70) by $0.58.

Institutional Trading of GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. DekaBank Deutsche Girozentrale bought a new stake in GT Biopharma, Inc. (NASDAQ:GTBP) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned approximately 77.02% of GT Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 8.15% of the company’s stock.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.